The Polygenic Risk Scores (PRS) study, involving DHC, was recently published in Nature Genetics (impact factor 38). The paper, entitled Improving Polygenic Prediction in Ancestrally Diverse Populations, is the result of a multi-year collaboration between DHC, Harvard Medical School, Broad Institute, and Shanghai Jiao Tong University. 

In 2016, DHC has already carried out precision medical big data research cooperation with Harvard-MIT Broad Institute and Shanghai Jiao Tong University to jointly promote new technology optimization and innovation in the medical industry. The published paper is one of the achievements of DHC's pioneering and improving new algorithms based on genomic big data.

As a member of Stanley Global Asia Initiatives, Shi Wenzhao, Chairman and CEO of DHC, participated in the research paper

 Genetic information to predict the disease and health status of individuals has important clinical applications.Multi-gene risk scoring algorithms are currently promising methods for predicting disease risk, and the development of their related fields has received widespread attention.However, the current algorithm has inherent biases that may affect the prediction effect in cross-ethnic populations. DHC, in collaboration with an international collaborative team, has promoted a new PRS prediction method, PRS-CSx, with its own big data technology precipitation and innovation strength, which provides algorithmic support for the study's small sample prediction model.This method exploits genetic information from several different populations and predicts a large number of phenotype-related indicators that can be useful for more accurate prediction of disease risk in different ethnic populations worldwide. This has important implications for the prediction of health and clinical approaches in Chinese or Asian populations.

DHC will continue to take advantage of the core technology of medical big data and artificial intelligence, and work together with the first-class institutions at home and abroad to promote the specific application of the new algorithm of multi-gene risk scoring in the clinic, thus creating the infinite health state of people with the power of technology and boosting the development of China's health.